Pharmacogenomics in Asia

Pharmacogenomics

Volumn 5, Issue 8, 2004, Pages 1023-1027

  Tamaoki, Mieko ^a   Gushima, Hiroshi ^a   Tsutani, Kiichiro ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

China; Japan; Pharmacogenetics; Pharmacogenomics; Republic of Korea; Singapore; Taiwan

Indexed keywords

IMATINIB; INTERFERON; RITUXIMAB; TRASTUZUMAB;

ARTICLE; ASIA; ASIAN; BLOOD SAMPLING; CHINA; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG RESEARCH; GENETIC POLYMORPHISM; GEOGRAPHIC DISTRIBUTION; GOVERNMENT; HELICOBACTER PYLORI; HEPATITIS C; HUMAN; JAPAN; KOREA; MEDICAL ETHICS; PHARMACOGENOMICS; POPULATION DISTRIBUTION; POPULATION RESEARCH; PRACTICE GUIDELINE; RACE DIFFERENCE; SINGAPORE; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; TAIWAN;

ASIA; BIOETHICS; DRUG INDUSTRY; PHARMACOGENETICS; RESEARCH SUPPORT;

EID: 11044229100     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.5.8.1023     Document Type: Article

References (2)

1. Sumino Y: Research Activities at the Pharma SNP Consortium: research into pharmacokinetic gene polymorphisms in the Japanese population. GOR 6(2), 1-7 (2004).
2. Council for International Organizations of Medical Sciences (Switzerland): Pharmacogenomics - Towards improving treatment with medicines. Geneva (2004).